Private equity firms River Head Capital and Ping An Capital led $186m Series B financing round in Lepu Biotech, a biotechnology startup. SDIC, Haitong Innovation Capital Management and State New Central Enterprises Operating Investment Fund also participated in this round. "Riverhead Capital highly recognizes Lepu Biotech’s leading advantages in terms of team experience, product pipeline, R&D capabilities and future commercialization. We are also very happy to cooperate with Lepu Biotech to build an integrated tumor immunotherapy platform based on the company’s rich R&D experience and product pipeline in the fields of antibodies, ADC and oncolytic viruses around tumor immunity and targeted therapy," Shi Shenghao, Riverhead Capital Managing Director.